By comparison, they found that it took only nine hours for blood glucose levels to return to their original values in control models treated with insulin by the normal route of subcutaneous injection.

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

Camurus’ Oczyesa receives European marketing authorization for treatment of acromegaly: Lund, Sweden Wednesday, July 2, 2025, 17:00 Hrs [IST] Camurus, an international, science- ...

Global Safety Syringes Market is valued at approximately USD 7096.94 million in 2022 and is anticipated to grow with a healthy growth rate of more than 4.5% during the forecast period 2023-2030.

The global safety syringes market, valued at approximately USD 7.1 billion in 2022, is projected to grow at a steady compound annual growth rate (CAGR) of over 4.5% during the forecast period from ...

Among the many things columnist Candace Semien had to learn while living with lupus were the types and function of various ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, ...

A recent webinar from BD shared important insights into patient fear and anxiety over self-injection and how the right device ...

Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress underway in London.

Small, 3D-printed devices, designed to be implanted directly under the skin, could allow people with type 1 diabetes to ...